Biomarker identified in relation to pazopanib in refractory urothelial cancer

Share :
Published: 13 Apr 2012
Views: 4351
Dr Andrea Necchi - National Cancer Institute of Milan, Italy

Dr Necchi presented the results from a study involving the antiangiogenic drug pazopanib at AACR 2012 in Chicago. The results revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumour response to the therapy.